SUMMARISED CONSOLIDATED RESULTS

FOR THE YEAR ENDED **30 SEPTEMBER 2018** AND CASH DIVIDEND DECLARATION

Group Overview

Excellent results

Revenue	Cash generated from operations	Normalised EBITDA
+12.9%	**+18.0%**	**+10.7%**
to R23.5 billion	to R5.5 billion	to R5.5 billion

Headline earnings per share (HEPS)	Normalised earnings per share	Final dividend
+40.6%	**+17.4%**	**+11.1%**
to 108.8 cps	to 110.2 cps	to 50 cps

2018: Group Overview

Strong operational performance across the Group

Life Healthcare southern Africa (SA):

- Positive paid patient day (PPD) growth
- Excellent year-on-year growth in complementary and healthcare services
- Good improvement in clinical quality outcomes
- Annual PPD growth impacted by lower admissions for pneumonia related conditions in Q4
- Our investment in future growth projects resulted in higher corporate costs

Scanmed S.A. (Scanmed):

- Successful business turnaround driven by the management team
- Business restructured and well-positioned to execute future growth initiatives

2018: Group Overview

Strong operational performance across the Group

Alliance Medical Group Limited (Alliance Medical):

- Solid performance driven by strong PET-CT wave 1 growth
- Obtained four PET wave 2 contracts
- Integrated diagnostic centre (IDC) sign-up in the United Kingdom (UK) ahead of plan
- Successful transition from short-term to long-term contracts continues
- Italy and Ireland delivering good results
- Integration of business processes and systems is underway

Max Healthcare Institute Limited (Max):

- Accepted an offer for our 49.7% equity shareholding in Max for approximately R4.3 billion before costs
- Transaction completion is subject to regulatory approval

2018: Group Overview

Strategic focus areas

- Successful strategy implementation of diversifying across business lines and territories
- Over one third of our business comes from non-acute sources

Revenue (%)



Acute vs non-acute revenue (%)



EBITDA (%)



2018: Group Overview

Strategic focus areas

Operational excellence:

- Group has a history and culture of driving operational excellence
- **H2 performance:**
  - EBITDA margin improvement:
    - Life Healthcare southern Africa acute and complementary
    - Alliance Medical

Quality:

- Clinical quality of paramount importance with a focus on measuring and reporting and expanding our clinical quality initiatives
- **H2 performance:**
  - Improved quality outcomes and patient experience
  - Introduction of clinical protocols covering maternity and stroke
  - Reporting of quality outcomes on a per hospital basis

Group-wide integration:

- Focus on driving Group wide integration
- **H2 performance:**
  - Driving Group wide synergies in operations, clinical quality, process automation and standardisation
  - Strengthening of data analytics across the Group

Growth:

- Grow the Group to an international healthcare provider, while still focussing heavily on SA growth and implementation of new initiatives
- Continue with the complementary services growth strategies and broaden our service offering outside of the acute spectrum
- **H2 performance:**
  - Good revenue growth of 12.9%
  - Positive PPD growth in SA
  - Continued good growth in complementary services
  - Strong PET-CT growth in Alliance Medical
  - Continued Scanmed turnaround
  - Increasing revenue from non-acute sources:
    - FY 2018: 35%
    - H2 2018: 36%

Life HEALTHCARE Group

Operational Review

Dr Shrey Viranna | Group CEO

Southern Africa

Southern Africa

Business review: steady increase in PPDs, revenue and EBITDA

	30 Sept 2018	30 Sept 2017	Change %
PPD GROWTH	**1.1%**	-1.7%	
REVENUE	**R 17 240m**	R 15 890m	8.5%
EBITDA	**R 4 289m**	R 4 049m	5.9%
EBITDA MARGIN	**24.9%**	25.5%	

- Solid PPD growth across all business units with strong growth in complementary services of over 5.0%
- Good revenue growth enhanced by complementary services growth of 14.0% and strong healthcare services growth of 28.8%
- Acute growth of 6.9%:
  - Revenue / ppd: 6.2%
  - PPD growth: 0.7%
- Positive EBITDA growth. Margins impacted by:
  - Double-digit healthcare services revenue growth at lower margins
  - Increased corporate costs due to investment in future growth projects

Southern Africa

Business review: capacity growth and utilisation

Capacity growth

	FY 2018	H1 2018	H2 2018
Bed additions at existing facilities	**131**	88	43
Renal dialysis stations	**15**	6	9

- Conservative growth in brownfield expansion beds across six hospitals
  - Life Midmed
  - Life St Mary's Private
  - Life Queenstown Private
  - Life Cosmos
  - Life The Crompton
  - Life Entabeni

Occupancy %



- Acute H2 occupancy impacted by lower pneumonia and upper respiratory (MDC04) admissions
- If the 2018 Q4 PPDs had been in line with 2017 then full year PPD growth would have been c. 2.0%

MDC04 PPD impact

	2018	2017	%
H1	**119 882**	118 835	0.9%
Q3	**77 411**	73 494	5.3%
Q4	**70 497**	94 189	(25.2%)
FY	**267 790**	286 518	(6.5%)

Healthcare Services

Strong growth in revenue

Revenue (R'm)



EBITDA (R'm)



- **Life Esidimeni:**
  - Positive engagement with Department of Health resulting in re-admission of 700 Gauteng mental healthcare users
  - 39 additional beds
  - Renewal of Shiluvana contract
- **Life Employee Health Solutions:**
  - Newly acquired occupational health and wellness business resulted in inherited contracts obtained at lower margins
  - Loss of major contract in H1 2018 impacting results and margins
  - Business being re-structured with new management. Well positioned for new growth with improved margins

5 Year Revenue Split

Business review: continued growth across key businesses

Revenue (R'm)



- **Underlying acute and complementary margins**
  - Overall margins declined from 25.5% to 24.9%. Lower margins within healthcare services (HCS) and increased corporate costs due to investment in future growth projects
  - Excluding healthcare services and corporate – EBITDA margins in the acute / complementary services businesses improved

Acute/complementary EBITDA margin (excl. HCS & corporate)



Quality

Quality outcomes and patient experience continue to show overall improvement

	30 Sept 2018	30 Sept 2017	Measure
Patient quality and safety measures			
HAI (Healthcare associated infection)	**0.41**	0.42	Per 1 000 PPDs
VAP (Ventilator associated pneumonia)	**1.09**	1.48	Per 1 000 ventilator days
SSI (Surgical site infection)	**0.99**	0.96	Per 1 000 theatre cases
CLABSI (Central line associated bloodstream infection)	**0.99**	0.85	Per 1 000 central lines
CAUTI (Catheter associated urinary tract infection)	**0.31**	0.40	Per 1 000 catheter days on one line
Patient safety adverse event	**2.68**	2.69	Per 1 000 PPDs
Medication adverse events	**1.10**	1.13	Per 1 000 PPDs
Falling adverse events	**0.68**	0.71	Per 1 000 PPDs
Pressure ulcers	**0.12**	0.13	Per 1 000 PPDs
Procedure related adverse events	**0.55**	0.51	Per 1 000 PPDs
Rehabilitation outcome measures			
FIM™/FAM score	**0.90**	1.00	Standardised assessment of 18 metrics widely used in rehabilitation
Mental health outcome measures			
MHQ14 efficiency	**2.20**	2.50	Average gain/PPD
Patient experience			
Definitely recommend	**70.7%**	70.0%	
Patient experience	**84%**	84%	

Operational Review

Dr Shrey Viranna | Group CEO

International

Alliance Medical

Overview

UK

DI static sites	33
PET-CT national contract sites	32
Mobiles	45

Revenue %	48%

Number of machines

MRI	65
CT	14
PET-CT	36
Cyclotrons	4

MRI / CT / other	48%
PET-CT / Radiopharmacy	52%
Public / Private	85% / 15%

Italy

Owned clinics	33
Static sites	11

Revenue %	31%

Number of machines

MRI	50
CT	23
PET-CT	4
Cyclotron	1

MRI / CT / other	95%
PET-CT / Radiopharmacy	5%
Public / Private	63% / 37%

Ireland

Operating sites	23

Revenue %	10%

Number of machines

MRI	27
CT	8
PET-CT	1

MRI / CT / other	94%
PET-CT	6%
Public / Private	39% / 61%

Other geographies

Spain, Netherlands, Germany, Finland, Bulgaria, Norway, Switzerland, Austria, US, Poland

Revenue %	11%

Cyclotrons	4

MRI / CT / other	35%
PET-CT / Radiopharmacy	65%

Alliance Medical

Stable overall performance with investment in future growth

For 12 months	30 Sept 2018	Piramal	H2 2018	H1 2018	30 Sept 2017	Change %
Revenue (£'m)	**283**	4	144	135	261	8.4
Normalised EBITDA (£'m)	**67**	(3)	38	32	69	(2.9)
Normalised EBITDA margin	**23.7%**		26.4%	23.7%	26.4%	

- Revenue grew by 8.4% on the back of strong PET-CT growth in the UK, good northern Europe growth and a solid performance from Italy and Ireland
- Excellent H2 performance with revenue growing by 6.7% and EBITDA by 18.8%

Normalised EBITDA margin (%)



Alliance Medical

UK

- **Molecular imaging (MI):**
  - PET wave 1
    - MI growth underpinned by 10 year PET wave 1 contract
    - Continued strong PET-CT volume growth of 15.2%
    - Growth benefitting from roll-out of static PET-CT sites
    - Pricing certainty until December 2025
  - PET wave 2
    - Successful with four PET wave 2 contracts
      - one contract in London
      - three contracts at existing PET-CT sites
    - Fixed price contracts with 7-year term with a 3-year option
  - Radiopharmacy
    - The strong growth in PET-CT resulted in operational challenges
    - Cyclotron upgrade is on track for December 2018 which will resolve supply issues in the short-term
    - Additional capacity is being introduced towards the end of FY 2019 to cater for the continued growth in PET-CT

PET-CT as a % of UK revenue



PET-CT Contract scan volumes



Alliance Medical

UK

- **Diagnostic imaging (DI):**
  - Strategic focus continues to be partnership solutions with hospital trusts
  - Alliance Medical UK benefitting from the move away from mobile infrastructure / short-term or spot contracts to static long term facilities and contracts
  - 12 long-term contracts signed for IDC's
  - Opened the first UK IDC in March 2018 at Colchester

Growth in longer-term contracts



Service starts with a single MRI	Service evolves to an MRI static supported by PET-CT & MRI mobiles	Service transitions to an Integrated Diagnostic Centre

Mobile

Mobile

Mobile

Static

Fully Integrated Diagnostic Centre

- 1 PET-CT
- 3 MRIs
- Nuclear medicine
- Mobile pad

Alliance Medical

Italy and Ireland

Italy:

- Private clinics MRI and CT volumes increased 14% on the back of increased volumes and the acquisitions of:
  - Albaro Clinic, acquired in H1 2017, performing ahead of business plan
  - IMED, acquired in March 2018 for £32.7 million, operating a group of six diagnostic clinics in the Veneto region in Italy
  - Centro Alfa, acquired in September 2018 for £0.8 million and operates out of Modena in Italy
- Growth in clinics business enables growth in private volumes
- Lower margin static contracts were exited

Public and private revenue



Ireland:

- Continues to show solid volume growth in clinics, statics and mobiles
- Rolling out an outpatient diagnostic clinic model:
  - Similar to the Italy clinic model and what is being introduced in the UK
  - In partnership with one of the large private hospital groups in Ireland

Public / private split



Europe

Alliance Medical northern Europe / clinical trials and Scanmed

Northern Europe:

- Good revenue growth on the back of the Life Radiopharma acquisition in H2 2017
- Growth is within the context of a lower EBITDA margin
- Acquisition created the largest European integrated radiotracer supply and imaging organisation, extending Alliance Medical's molecular imaging presence in northern Europe

Product development / clinical trials:

- Business of Piramal Imaging S.A and three subsidiaries (Piramal) acquired in June 2018
- Piramal focusses on development of innovative molecular imaging agents addressing neurological, oncological and cardiovascular diseases. Includes Food and Drug Administration (FDA) approved product for assisting in the diagnosis of Alzheimer's disease (Re-branded Life Molecular Imaging)

Poland:

- Strong business turnaround
- Good volume growth in cardiology
- Continued focus on operational efficiency and costs optimisation

Revenue (PLN'm)



EBITDA (PLN'm)



Financial Review

Pieter van der Westhuizen | Group CFO

Highlights

Good performance
across all territories with improved performance in H2

Strong cash generated from operations
for the year with cash generated from operations up 18.0%

Final cash dividend of 50 cents per share
Total dividend of 88 cents per share (up 10.0%)

Normalised earnings per share up 17.4%
on the back of good operational performance and the benefit of lower interest cost

Summarised profit or loss

Group

	2018 R'm	2017 R'm	%
Revenue	**23 488**	20 797	12.9
Normalised EBITDA	**5 535**	5 001	10.7
Normalised EBITDA margin	**23.6%**	24.0%	
EBITA	**4 402**	4 030	9.2
Amortisation	**(537)**	(439)	22.3
Operating profit	**3 848**	3 620	6.3
Net finance costs	**(962)**	(1 137)	(15.4)
Associates and joint ventures	**(105)**	(15)	(>100)
Profit before tax	**2 837**	1 934	46.7
Tax	**(923)**	(815)	13.3
Non-controlling interest	**(339)**	(305)	11.1
Attributable profit	**1 575**	814	93.5

Revenue growth largely due to Alliance Medical included for 12 months compared to 10.3 months in 2017 and the weakening of the rand against the pound sterling, euro and polish zloty

EBITDA impacted by increased cost base and investments for future growth

Amortisation of intangibles normalised for Alliance Medical acquisition and the impact of additional acquisitions

Max included for nine months

Effective tax rate reduced from 42.1% to 32.5% largely due to once-off costs included in 2017

Financial Results

Group

	2018 R'm	2017 R'm	%
Revenue	**23 488**	20 797	12.9
Southern Africa	**17 240**	15 890	8.5
Alliance Medical	**4 922**	3 812	29.1
Alliance Medical – product dev	**66**	-	>(100)
Poland	**1 260**	1 095	15.1
Normalised EBITDA	**5 535**	5 001	10.7
Southern Africa	**4 289**	4 049	5.9
Alliance Medical	**1 206**	908	32.8
Alliance Medical – product dev	**(45)**	-	>(100)
Poland	**85**	44	93.2
Normalised EBITDA margin (%)	**23.6%**	24.0%	
Southern Africa	**24.9%**	25.5%	
Alliance Medical (excl. product dev)	**24.5%**	23.8%	
Poland	**6.7%**	4.0%	

Increased overheads related to capacity building, empowerment spend and governance

Alliance Medical included for 12 months in 2018 vs. 10.3 months in 2017

Acquisition of clinical trials business in June 2018. Clinical trials for neurological diseases as well as cancer detection

Stronger performance from Poland on back of contract renewals and integration efforts

1PLN = ZAR3.66 (30 Sept 2018) 1GBP = ZAR17.60 (30 Sept 2018)
1PLN = ZAR3.44 (30 Sept 2017) 1GBP = ZAR16.93 (30 Sept 2017)

Life Healthcare Group

Financial Results

Group

	30 Sept 2018	30 Sept 2017	Change %
Weighted average number of shares (million)	**1 451**	1 310	10.8
EPS (cents)	**108.6**	62.2	74.6
Impairments of assets and investments	**2.3**	12.8	
Profit on remeasuring previously held interest in associate to fair value	**-**	(0.4)	
(Profit)/loss on disposal of property, plant and equipment	**(2.1)**	2.8	
HEPS (cents)	**108.8**	77.4	40.6
Fair value adjustment to contingent consideration	**1.2**	(3.3)	
Transaction costs relating to acquisitions	**2.6**	20.4	
Gain on derecognition of lease assets and liabilities	**(4.9)**	-	
Other	**2.5**	(0.6)	
Normalised EPS (cents)	**110.2**	93.9	17.4
Effect of Max	8.1	2.1	
Normalised EPS excluding Max (cents)	**118.3**	96.0	23.2
Normalised EPS excluding amortisation (cents)	**139.3**	120.6	15.5

Summarised Consolidated Statement of Financial Position

	2018 R'm	2017 R'm
Non-current assets	**30 558**	31 459
Property, plant and equipment	**12 243**	11 131
Goodwill	**12 991**	12 170
Intangible assets	**4 093**	4 111
Investment in Max (reclassified as held for sale)	**-**	2 960
Other	**1 231**	1 087
Current assets (excluding cash and asset classified as held for sale)	**4 249**	4 004
Asset classified as held for sale	**2 841**	-
Cash and cash equivalents	**1 494**	1 176
Total assets	**39 142**	36 639
Total shareholders' equity	**16 202**	15 551
Non-current liabilities	**14 764**	9 991
Interest-bearing borrowings	**12 870**	7 786
Other non-current liabilities	**1 894**	2 205
Current liabilities (excluding interest-bearing borrowings)	**5 090**	4 796
Interest bearing borrowings	**3 086**	6 301
Total equity and liabilities	**39 142**	36 639
Net debt	**14 950**	13 361
Net debt to normalised EBITDA (covenant 3.5x)	**2.73**	2.55

Debt and debt facilities

Funding	30 Sept 2018 R'm	Weighted avg. cost of debt (post-tax)	30 Sep 2017 R'm	Weighted avg. cost of debt (post-tax)
Acquisition funding				
ZAR	**3 551**	7.31	4 851	7.32
PLN	**830**	3.75	801	3.77
GBP	**1 311**	2.42	992	2.26
Capex funding - ZAR	**3 837**	6.16	2 498	6.67
Poland	**134**	3.05	148	3.05
Alliance Medical	**4 789**	2.11	3 157	1.96
Capitalised finance leases				
ZAR	**548**	8.68	670	9.22
PLN	**259**	4.45	253	4.45
GBP	**697**	3.53	717	3.65
Working capital - ZAR	**488**	5.76	450	6.12
	16 444	4.64	14 537	5.28

Available bank facilities



Cash Flow

Group

	30 Sept 2018 R'm	30 Sept 2017 R'm	Change %
Cash generated from operations	**5 503**	4 663	18.0
Net interest paid	**(863)**	(621)	
Tax paid	**(1 065)**	(891)	
Maintenance capex	**(878)**	(837)	
Minority distributions	**(252)**	(261)	
Staff schemes	**(72)**	(125)	
Free cash flow before transaction costs and non-recurring interest	**2 373**	1 928	23.1
Non-recurring interest	**-**	(427)	
Transaction costs paid	**(38)**	(210)	
Growth capex	**(1 366)**	(819)	
Investments, net of cash (incl. contingent considerations paid)	**(1 131)**	(10 301)	
Net cash flow after capex and investments	**(162)**	(9 829)	>100
Free cash per share (before transaction costs and non-recurring interest (cents)	**163.5**	147.2	11.1



Distribution

Distributions	Cents per share	R'm
Interim 2017	35	504
Final 2017	45	652
Total 2017	**80**	1 156
Interim 2018	38	556
Final 2018	50	734
Total 2018	**88**	1 290

- The Group's dividend policy is to pay a progressive dividend that takes into account the underlying earnings and available funding of the Group both in southern Africa and internationally, while retaining sufficient capital to fund ongoing operations and growth projects, as well as, manage gearing to acceptable levels.

Outlook

Dr Shrey Viranna | Group CEO

2019 : Outlook

Southern Africa:

- Capex spend for FY2019 for approximately R1.2 billion, of which R850 million relates to maintenance capex
- Conservative brownfield bed expansion and addition of a new 80 bed mental health facility, opening in Q2 2019

Alliance Medical:

- Capex spend for FY2019 of approximately £67million, of which £25million relates to maintenance capex
- UK:
  - Continued strong PET-CT growth in PET wave 1
  - Start of PET wave 2 contracts in Q2. Expected c.10% increase in PET-CT scan volumes but dilutive in year one due to initial set-up costs and different pricing model
  - Continued roll-out of IDCs and a focus on signing additional contracts
  - Continue to shift the business to longer-term sustainable contracts – c.75% in UK in longer-term contracts in FY2019
  - Stabilisation of Radiopharmacy business
- Ireland:
  - Continued good growth and roll-out of outpatient diagnostic clinics
- Italy:
  - Continued growth in clinic business on the back of steady volume growth and potential select acquisitions

Scanmed:

- Capex spend for FY2019 of approximately PLN20million, of which PLN14million relates to maintenance capex
- Revenue growth and EBITDA margins in line with FY2018

2019: Strategic Focus

- Continued focus on evolving the Group's operating model leveraging off existing assets and existing scale

Employee Health Solutions 381 sites 579 000 lives	**Off-site clinics** 17	**Government / public sector** 10 PPPs 3 119 beds	**Acute hospital business** 50 hospitals 8 224 beds	**Complementary services** 15 units/831 beds 318 renal stations 5 oncology units	**Step down facilities home nursing**
Medical services 350,000 lives	**Ambulatory clinics** 23		**Acute hospital business** 2 Hospitals 3 specialist clinics 12 cathlabs	**Diagnostics** 13 countries Diagnostic imaging Molecular imaging Radiopharmacy Clinical trials	

Southern Africa (top row) International (bottom row)

2019: Strategic Focus

- Continued focus on evolving the Group's operating model leveraging off existing assets and existing scale

Employee Health Solutions	Off-site clinics	Government / public sector	Acute hospital business	Complementary services	Step down facilities Home Nursing
• Continued good growth • Focus on improved margins • Integration across the whole business	• Utilisation of existing off-site clinics • A&E model re-structure • Pilot of MyLife primary care clinic	• Increased collaboration with the public sector across the healthcare spectrum	• Expansion of clinical quality initiatives • Review of asset portfolio	• Continued expansion of complementary lines of business • Diagnostics opportunity	• Broaden service offering • Utilise existing Life Healthcare risk based pricing structures

Integration: unlocking value

- Group wide integration driving synergies in operations, procurement, standardisation and clinical quality

Diagnostics:

- Growth on the back of operational excellence with select bolt-on acquisitions

Life HEALTHCARE Group

Questions

Revenue	Cash generated from operations	Normalised EBITDA
+12.9% to R23.5 billion	**+18.0%** to R5.5 billion	**+10.7%** to R5.5 billion

Headline earnings per share (HEPS)	Normalised earnings per share	Final dividend
+40.6% to 108.8 cps	**+17.4%** to 110.2 cps	**+11.1%** to 50 cps

Annexures

Southern Africa

Business review



	Acute hospitals	Complementary services	Healthcare services
Proportion of SA revenue	87.9%	5.6%	6.5%
4 year revenue CAGR	7.2%	16.0%	6.8%
Facility overview	**50 acute hospitals:** 8 224 beds 2 023 000 PPDs 590 000 admissions 340 000 theatre cases 30 000 births 14 000 cathlab cases	**7 acute rehabilitation units** 319 beds **8 mental health units:** 512 beds **26 renal dialysis units:** 318 stations **5 oncology units**	**10 PPP facilities** 3 119 beds **301 occupational health sites** 211 000 lives **80 wellness sites:** 368 000 lives

Southern Africa

Market dynamics frame the opportunity for growth

Ageing



Chronic disease



Funder PPDs



Implications

- Increasing proportion of PPDs and revenue come from patients above 50 years of age

	% Difference
LOS differential patients >50 years vs <50 years	**+34%**
Revenue / admission differential patients >50 years vs <50 years	**+78%**

- Increasing proportion of admissions and revenue come from patients with chronic diseases

	2018	2017	2013
% of admissions: chronic	**40%**	39%	37%
% of revenue: chronic	**55%**	55%	52%

Southern Africa

Business review: medical / surgical growth

Total medical / surgical split as a % of PPDs



Acute medical / surgical split as a % of PPDs



- Continued growth of medical cases on the back of complementary growth
- Continued growth in medical cases despite the drop in MDC04 admissions

Alliance Medical

Positive diagnostic growth drivers frame the opportunity for growth

Ageing population

- 36% of MRIs and 60% of CTs performed on people over 60 years of age



Growth in relevant condition requiring complex diagnostic imaging

Urgent GP referrals for suspected cancer have increased by 60% in the UK over the last 5 years

- c. 50% CTs, 10% MRIs & 98% PET-CTs linked to cancer

Emphasis on early diagnosis

Reduced downstream costs, improved clinical outcomes and survival rates

Technology improvements

Leading to better scan quality and new applications for scans

Increased A&E admissions

Increased use of scanning within A&Es.
In the UK major A&E visits up by 7.2% over last 5 years

Sources: Populationpyramid.net; NHS England Analytical services; NHS Key statistics 2018

Alliance Medical

UK diagnostic volumes are predicted to continue to grow strongly

Market CAGRs

2015-17	2025 Forecast
5.6%	5.6%
27%	12%
6.2%	6.2%

UK MRI scans (million)



UK PET-CT (000)



UK CT scans (million)



Source: Diagnostic Imaging dataset – annual statistical release

Life Healthcare Group

Life HEALTHCARE Group